Buy the Dip on Aphria Stock’s Post-Earnings Plunge

Here’ why I’d buy Aphria’s stock after is share price plunged after earnings on Thursday.

crashing stocks

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Cannabis producer Aphria Inc.’s (TSX:APHA)(NASDAQ:APHA) stock price had fallen more than 18% by mid-day during Thursday’s trading session. Investors freaked out at the Canadian pot firm’s revenue declines in its quarterly earnings results for the three months ending August 31 this year. Although Aphria’s fiscal Q1 2021 financial results missed analyst expectations, I believe a sudden near 20% decline in its stock price is overdone.

Perhaps this is another buying opportunity for long-term investors in the marijuana play.

How did Aphria’s latest earnings disappoint stock investors?

The company’s net revenue of $145.7 million during the three months to August 31, 2020, fell significantly short of the $159.6 million analysts had predicted for the quarter. Total sales declined sequentially by 4% from $152.2 million in revenue generated in the previous quarter.

That said, the company’s net loss of $5.1 million for the quarter was much better than a $9.5 million loss the market had anticipated.

APHA’s revenue miss was mainly a function of a significant dip in pharmaceuticals distribution revenue in Europe due to the COVID-19 pandemic. Distribution revenue declined by 17% sequentially due to low patient traffic to medical offices during the coronavirus outbreak.

The pandemic’s impact was also felt in a 5.4% sequential decline in medical cannabis sales in Canada. Actually, there was a 15.8% sequential decline in medical cannabis volumes that was partially offset by an 11.3% increase in average selling prices. The number of registered patients in Canada declined during the period as new patients could not be onboarded during the national health crisis.

Investors freaked out on the top-line numbers, and they seem to have ignored the bright side portrayed in Aphria’s latest quarterly financial results.

The good numbers in APHA’s mixed earnings results

If Aphria is regarded as a cannabis stock, why should investors freak out when its side business becomes volatile?

The weakness in APHA’s operating results was in a pharmaceuticals distribution business in Europe. Distribution revenues used to contribute the most to total net sales, but they contribute very little to the company’s operating earnings in the form of Adjusted EBITDA.

I would wish to point out that, if investors look for growth in the business, their focus should be not on its slow growth and low margin distribution sales, but on the company’s growing hot and high margin cannabis segment. Interestingly, that’s where the beautiful numbers were mostly loaded.

Aphria grew its cannabis sales by 18% sequentially to $62.5 million over three months. Its marijuana gross profit jumped 106% year-over-year to $31.5 million for the quarter. Most noteworthy, its adjusted EBITDA from marijuana operating marijuana business surged 11% sequentially to $10.4 million.

The accounting net loss of $5.1 million overshadowed a nice 419% year-over-year growth in operating income to $20.7 million. The net loss was mainly caused by a $19.3 million in foreign exchange losses. It’s tricky to compare the net loss for the latest quarter against a $16.4 million profit last year.

The latter mainly resulted from fair value gains in investments and unrealized gains on debentures. Such non-operating and largely non-recurring numbers distort the operating results in a significant way.

Most noteworthy, the sudden shock in distribution revenue overshadowed a 25% sequential surge in distribution operating earnings, as seen in an adjusted EBITDA of $2.4 million.

Although weaker, distribution operations sales had a higher gross margin of 14.4%, showing a margin expansion from the 12.1% reading printed during the previous quarter.

Foolish bottom line

Aphria was a victim of the pandemic, yet it still produced hilarious growth numbers in its core cannabis business. The company is adequately funded with $400 million in cash and cash equivalents on the balance sheet, dilution isn’t a big concern yet.

I am very much tempted to conclude that the sudden plunge in the company’s stock price is overdone, and focused too much on its soon to be non-core distribution segment as it starts distributing medical cannabis through CC Pharma in Germany.

This sudden dip is a lucrative buying opportunity.

Should you invest $1,000 in Artis Real Estate Investment Trust right now?

Before you buy stock in Artis Real Estate Investment Trust, consider this:

The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and Artis Real Estate Investment Trust wasn’t one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years.

Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the “eBay of Latin America” at the time of our recommendation, you’d have $20,697.16!*

Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 29 percentage points since 2013*.

See the Top Stocks * Returns as of 3/20/25

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Confidently Navigate Market Volatility: Claim Your Free Report!

Feeling uneasy about the ups and downs of the stock market lately? You’re not alone. At The Motley Fool Canada, we get it — and we’re here to help. We’ve crafted an essential guide designed to help you through these uncertain times: "5-Step Checklist: How to Prepare Your Portfolio for Volatility."

Don't miss out on this opportunity for peace of mind. Just click below to learn how to receive your complimentary report today!

Get Our Free Report Today

More on Cannabis Stocks

a person watches a downward arrow crash through the floor
Stocks for Beginners

Plummet Alert: Is This TSX Growth Stock a Bargain or a Falling Knife?

This growth stock was once a major winner, but can investors wait for more?

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

What to Know About Canadian Cannabis Stocks for 2025

Let's dive into two top Canadian cannabis stocks and where they may be headed from here (given the recent moves…

Read more »

Researcher works in hemp field
Cannabis Stocks

Aurora Cannabis Stock Is up 46% in 2025: Are Investors Going From 5 Years of Pain to a 2025 Gain?

Shares of Aurora Cannabis have staged a comeback in 2025, outpacing the broader markets comfortably. Is ACB stock a good…

Read more »

A plant grows from coins.
Stocks for Beginners

3 Growth Stocks That Could Skyrocket in 2025 and Beyond

It could be a big year for these sectors, and these growth stocks in particular throughout 2025.

Read more »

money goes up and down in balance
Tech Stocks

2 TSX Stocks to Buy and 2 to Avoid in the Looming Trade War

The looming U.S.-Canada trade war has changed the business environment. Here are some TSX stocks to buy and avoid in…

Read more »

space ship model takes off
Cannabis Stocks

2 Canadian Stocks With Strong Momentum for 2025

Celestica Inc. (TSX:CLS) stock and Dollarama (TSX:DOL) stock have sustained strong price growth momentum for a long time.  Here’s why…

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Pot Stocks: Buy, Sell, or Hold in 2025?

Cannabis stocks remain a bit risky, but could long-term investors be in for more pain or far more profits?

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »